BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 7530400)

  • 1. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Sattentau QJ; Zolla-Pazner S; Poignard P
    Virology; 1995 Jan; 206(1):713-7. PubMed ID: 7530400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
    Finnegan CM; Berg W; Lewis GK; DeVico AL
    J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; NĂ¡das A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.
    Cordell J; Moore JP; Dean CJ; Klasse PJ; Weiss RA; McKeating JA
    Virology; 1991 Nov; 185(1):72-9. PubMed ID: 1718090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    Sattentau QJ; Moore JP
    J Exp Med; 1991 Aug; 174(2):407-15. PubMed ID: 1713252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.
    Poignard P; Fouts T; Naniche D; Moore JP; Sattentau QJ
    J Exp Med; 1996 Feb; 183(2):473-84. PubMed ID: 8627160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.
    Rathinakumar R; Dutta M; Zhu P; Johnson WE; Roux KH
    J Virol; 2012 Feb; 86(3):1820-31. PubMed ID: 22090143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
    Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore JP; Schulz T; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):33-9. PubMed ID: 7678970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
    Bouma P; Leavitt M; Zhang PF; Sidorov IA; Dimitrov DS; Quinnan GV
    J Virol; 2003 Jul; 77(14):8061-71. PubMed ID: 12829845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.
    Peachman KK; Wieczorek L; Polonis VR; Alving CR; Rao M
    Virology; 2010 Dec; 408(2):213-23. PubMed ID: 20961591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.